BIOMAT Database Logo BIOMAT Database Logo

A Randomized, Double-Blind, Double-Dummy Study of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Relative to Umeclidinium/Vilanterol Dry Powder Inhaler in COPD. 2019

François Maltais, and Gary T Ferguson, and Gregory J Feldman, and Gaëtan Deslee, and Arnaud Bourdin, and Harald Fjällbrant, and Agnieszka Siwek-Posłuszna, and Martin A Jenkins, and Ubaldo J Martin
Centre de Recherche, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Québec, QC, Canada. Francois.Maltais@med.ulaval.ca.

Glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI), formulated using co-suspension delivery technology, is the only approved fixed-dose combination long-acting muscarinic antagonist/long-acting β2-agonist (LAMA/LABA) delivered via MDI. Direct comparisons of GFF MDI versus other LAMA/LABAs have not previously been performed. We assessed the efficacy and safety of GFF MDI relative to umeclidinium/vilanterol dry powder inhaler (UV DPI) in patients with moderate-to-very severe chronic obstructive pulmonary disease (COPD). In this phase IIIb randomized, double-blind, double-dummy, multicenter, 24-week study, patients received GFF MDI 18/9.6 μg (equivalent to glycopyrronium/formoterol fumarate dihydrate 14.4/10 μg; two inhalations per dose, twice-daily; n = 559) or UV DPI 62.5/25 μg (one inhalation, once-daily; n = 560). Primary endpoints were change from baseline in morning pre-dose trough forced expiratory volume in 1 s (FEV1) and peak change from baseline in FEV1 within 2 h post-dose, both over 24 weeks. Additional lung function, symptom and safety endpoints were also assessed. For the primary endpoints, GFF MDI was non-inferior to UV DPI (using a margin of - 50 mL) for peak FEV1 (least squares mean [LSM] difference - 3.4 mL, 97.5% confidence interval [CI] - 32.8, 25.9) but not for trough FEV1 (LSM difference - 87.2 mL; - 117.0, - 57.4). GFF MDI was nominally superior to UV DPI for onset of action (p < 0.0001) and was nominally non-inferior to UV DPI for all symptom endpoints (Transition Dyspnea Index focal score, Early Morning/Night-Time Symptoms COPD instrument scores, and COPD Assessment Test score). Exacerbation and safety findings were similar between groups. Over 24 weeks of treatment, GFF MDI was non-inferior to UV DPI for peak FEV1, but not for morning pre-dose trough FEV1. GFF MDI had a faster onset of action versus UV DPI. There were no clinically meaningful differences between treatments in symptom endpoints. Both treatments were well tolerated with similar safety profiles. NCT03162055 (Clinicaltrials.gov) FUNDING: AstraZeneca.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012129 Respiratory Function Tests Measurement of the various processes involved in the act of respiration: inspiration, expiration, oxygen and carbon dioxide exchange, lung volume and compliance, etc. Lung Function Tests,Pulmonary Function Tests,Function Test, Pulmonary,Function Tests, Pulmonary,Pulmonary Function Test,Test, Pulmonary Function,Tests, Pulmonary Function,Function Test, Lung,Function Test, Respiratory,Function Tests, Lung,Function Tests, Respiratory,Lung Function Test,Respiratory Function Test,Test, Lung Function,Test, Respiratory Function,Tests, Lung Function,Tests, Respiratory Function
D001993 Bronchodilator Agents Agents that cause an increase in the expansion of a bronchus or bronchial tubes. Bronchial-Dilating Agents,Bronchodilator,Bronchodilator Agent,Broncholytic Agent,Bronchodilator Effect,Bronchodilator Effects,Bronchodilators,Broncholytic Agents,Broncholytic Effect,Broncholytic Effects,Agent, Bronchodilator,Agent, Broncholytic,Agents, Bronchial-Dilating,Agents, Bronchodilator,Agents, Broncholytic,Bronchial Dilating Agents,Effect, Bronchodilator,Effect, Broncholytic,Effects, Bronchodilator,Effects, Broncholytic
D002722 Chlorobenzenes Aromatic organic compounds with the chemical formula C6H5Cln.
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D005541 Forced Expiratory Volume Measure of the maximum amount of air that can be expelled in a given number of seconds during a FORCED VITAL CAPACITY determination . It is usually given as FEV followed by a subscript indicating the number of seconds over which the measurement is made, although it is sometimes given as a percentage of forced vital capacity. Forced Vital Capacity, Timed,Timed Vital Capacity,Vital Capacity, Timed,FEVt,Capacities, Timed Vital,Capacity, Timed Vital,Expiratory Volume, Forced,Expiratory Volumes, Forced,Forced Expiratory Volumes,Timed Vital Capacities,Vital Capacities, Timed,Volume, Forced Expiratory,Volumes, Forced Expiratory
D006024 Glycopyrrolate A muscarinic antagonist used as an antispasmodic, in some disorders of the gastrointestinal tract, and to reduce salivation with some anesthetics. Glycopyrronium,Glycopyrronium Bromide,NVA 237,NVA-237,NVA237,Pyrrolidinium, 3-((cyclopentylhydroxyphenylacetyl)oxy)-1,1-dimethyl-, bromide,Bromide, Glycopyrronium
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

François Maltais, and Gary T Ferguson, and Gregory J Feldman, and Gaëtan Deslee, and Arnaud Bourdin, and Harald Fjällbrant, and Agnieszka Siwek-Posłuszna, and Martin A Jenkins, and Ubaldo J Martin
A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD.
November 2016, Respiratory medicine,
François Maltais, and Gary T Ferguson, and Gregory J Feldman, and Gaëtan Deslee, and Arnaud Bourdin, and Harald Fjällbrant, and Agnieszka Siwek-Posłuszna, and Martin A Jenkins, and Ubaldo J Martin
A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler.
January 2001, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology,
François Maltais, and Gary T Ferguson, and Gregory J Feldman, and Gaëtan Deslee, and Arnaud Bourdin, and Harald Fjällbrant, and Agnieszka Siwek-Posłuszna, and Martin A Jenkins, and Ubaldo J Martin
Bone and ocular safety of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a 52-week randomized study.
July 2019, Respiratory research,
François Maltais, and Gary T Ferguson, and Gregory J Feldman, and Gaëtan Deslee, and Arnaud Bourdin, and Harald Fjällbrant, and Agnieszka Siwek-Posłuszna, and Martin A Jenkins, and Ubaldo J Martin
Corrigendum to "A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD" [Respir. Med. 120 November 2016 16-24].
August 2017, Respiratory medicine,
François Maltais, and Gary T Ferguson, and Gregory J Feldman, and Gaëtan Deslee, and Arnaud Bourdin, and Harald Fjällbrant, and Agnieszka Siwek-Posłuszna, and Martin A Jenkins, and Ubaldo J Martin
Pharmacodynamic study of procaterol hydrochloride dry powder inhaler: evaluation of pharmacodynamic equivalence between procaterol hydrochloride dry powder inhaler and procaterol hydrochloride metered-dose inhaler in asthma patients in a randomized, double-dummy, double-blind crossover manner.
January 2005, Methods and findings in experimental and clinical pharmacology,
François Maltais, and Gary T Ferguson, and Gregory J Feldman, and Gaëtan Deslee, and Arnaud Bourdin, and Harald Fjällbrant, and Agnieszka Siwek-Posłuszna, and Martin A Jenkins, and Ubaldo J Martin
Formoterol as dry powder inhalation. A dose finding study in comparison with formoterol metered dose inhaler and placebo.
May 1992, Chest,
François Maltais, and Gary T Ferguson, and Gregory J Feldman, and Gaëtan Deslee, and Arnaud Bourdin, and Harald Fjällbrant, and Agnieszka Siwek-Posłuszna, and Martin A Jenkins, and Ubaldo J Martin
A randomized study of formoterol fumarate in a porous particle metered-dose inhaler in patients with moderate-to-severe COPD.
September 2014, Respiratory medicine,
François Maltais, and Gary T Ferguson, and Gregory J Feldman, and Gaëtan Deslee, and Arnaud Bourdin, and Harald Fjällbrant, and Agnieszka Siwek-Posłuszna, and Martin A Jenkins, and Ubaldo J Martin
Baseline Symptom Score Impact on Benefits of Glycopyrrolate/Formoterol Metered Dose Inhaler in COPD.
December 2017, Chest,
François Maltais, and Gary T Ferguson, and Gregory J Feldman, and Gaëtan Deslee, and Arnaud Bourdin, and Harald Fjällbrant, and Agnieszka Siwek-Posłuszna, and Martin A Jenkins, and Ubaldo J Martin
Comparison of Dry-Powder Inhaler and Pressurized Metered-Dose Inhaler Formulations of Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium in Patients with COPD: The TRI-D Randomized Controlled Trial.
January 2021, International journal of chronic obstructive pulmonary disease,
François Maltais, and Gary T Ferguson, and Gregory J Feldman, and Gaëtan Deslee, and Arnaud Bourdin, and Harald Fjällbrant, and Agnieszka Siwek-Posłuszna, and Martin A Jenkins, and Ubaldo J Martin
Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler in Chinese Patients with COPD: A Subgroup Analysis of KRONOS.
April 2020, Advances in therapy,
Copied contents to your clipboard!